How many syringe units is a sermorelin dose?

It depends on your water volume, which sets the concentration. A microgram dose from a milligram vial lands at a small unit mark, so the water volume matters more here than for a milligram-dosed compound. Enter both in the calculator, or read the combination off the reconstitution chart below.

When should sermorelin be taken?

The engine catalog specifies bedtime, and the dose row's frequency string says the same. The administration section on this page carries the catalog note verbatim rather than paraphrasing it. Growth hormone release is pulsatile and largest overnight, which is the reason the timing is part of the protocol rather than a convenience.

What does the experience level input change?

It selects a different row in the engine dose table, changing the opening dose, standard dose, upper dose and ceiling. At the highest level the dose table also allows splitting the daily amount across more than one administration, which the frequency column shows verbatim.

Does body weight change the sermorelin dose?

No. The engine catalog does not flag sermorelin weight sensitive and the dose calculator applies no generic weight scaling, so the tool leaves the target alone. Some peptides do carry a per-kilogram factor and the tool applies it for those.

Does sermorelin need cycling?

The engine catalog carries an on-period and an off-period for it, both shown on this page and used by the supplies plan.

Is sermorelin banned in drug-tested sport?

Yes. The World Anti-Doping Agency names sermorelin in the growth hormone releasing factors class of section S2, prohibited at all times, in and out of competition. The same class covers growth hormone releasing hormone analogues generally and growth hormone secretagogues. If you compete under anti-doping rules, check the current list directly.

When is sermorelin not appropriate?

The conditions table on this page lists every health condition the engine's contraindication matrix associates with this compound and its category, with the engine's own stated reason and whether it blocks, cautions, monitors or reduces the dose.

Where do the numbers on this page come from?

The dose table, the ceilings and the frequency come from the Klarovel engine's own dose table, the same rows the protocol generator doses from. Route, timing, cycling and weight sensitivity come from the engine catalog. Nothing on this page is a number someone typed into an article, which is the failure mode most dosing pages share.

Is this calculator free?

Yes. No account, no paywall, no usage limit. The protocol engine behind it is a separate product, but the calculator is open.

Does Klarovel sell this peptide?

No. Klarovel is the protocol layer: a questionnaire, a deterministic rules engine and a generated protocol. Any product is fulfilled by partner suppliers, not by Klarovel.

Is this medical advice?

No. It is arithmetic over published dose data, presented as a reference. It is not a prescription and not a recommendation to use any compound. Discuss peptide use with a qualified clinician.

Sermorelin dosage calculator

Sermorelin is dosed in micrograms at bedtime, and it is one of the few compounds here that once held a US marketing approval. Enter your vial size, water volume and experience level for the exact syringe mark.

Below the calculator: a full reconstitution chart, the dose envelope per experience level, the cycle length, a supplies plan, the health conditions that change the answer, and the references. Every dose figure is read from the Klarovel engine's dose table, never typed into the page.

How many milligrams are in your Sermorelin vial?

How much bacteriostatic water are you adding?

Syringe size

Experience with injectable peptides

Selects the dose row the engine would use, which changes the target, the upper bound and the ceiling together.

Body weight

The engine catalog does not flag Sermorelin weight sensitive, and the dose calculator applies no generic weight scaling, so this does not change the target. Inventing a per-kilogram rule would be worse than leaving it alone.

Age 65 or over

Standard dose at the beginner level

5.0 units

250 mcg

Concentration: 5 mg/ml
Injection volume: 0.05 ml
Doses per vial: 40

Frequency: once daily at bedtime. Timing: Bedtime. Route: subcutaneous.

Phase by phase, at your mix

The three phases in the order the engine escalates a dose, with the unit mark for each at 10 mg in 2 ml. Change the experience level, weight or age above and the whole table recomputes.

Dose and syringe units per titration phase
Phase	Dose	Draw	Doses per vial
Phase 1, opening dose	200 mcg	4.0 units	50
Phase 2, standard dose	250 mcg	5.0 units	40
Phase 3, upper dose	300 mcg	6.0 units	33
Ceiling, not exceeded	400 mcg	8.0 units	25

Doses read from the beginner row of dose_protocols, the engine's dose table. Unit marks are arithmetic over your vial size and water volume.

Sermorelin dose envelope by experience level

Every level side by side, unmodified. This is the raw dose table, so the shape of the ramp is visible instead of collapsed into a single recommended number.

Dose envelope per experience level
Experience	Opening	Standard	Upper	Ceiling	Frequency
Never used peptides	100 mcg	150 mcg	200 mcg	300 mcg	once daily at bedtime
Researched, not used	150 mcg	200 mcg	250 mcg	300 mcg	once daily at bedtime
Beginner	200 mcg	250 mcg	300 mcg	400 mcg	once daily at bedtime
Intermediate	250 mcg	300 mcg	400 mcg	500 mcg	once daily at bedtime
Experienced	300 mcg	400 mcg	500 mcg	500 mcg	once daily at bedtime or split into 2-3 doses

Every cell read verbatim from dose_protocols. Where a level repeats the same figure across columns, that is what the table holds: no ramp has been invented to fill the row.

Sermorelin reconstitution chart

Pre-calculated syringe units for every water volume against the dose figures this compound actually uses, at your selected vial size of 10 mg. A cell reading "n/a" means the draw exceeds a 100-unit syringe at that concentration.

Syringe units per water volume for each sourced dose figure
BAC water	Conc.	Opening200 mcg	Standard250 mcg	Upper300 mcg	Ceiling400 mcg
1 ml	10 mg/ml	2	2.5	3	4
1.5 ml	6.67 mg/ml	3	3.8	4.5	6
2 ml	5 mg/ml	4	5	6	8
2.5 ml	4 mg/ml	5	6.3	7.5	10
3 ml	3.33 mg/ml	6	7.5	9	12
4 ml	2.5 mg/ml	8	10	12	16
5 ml	2 mg/ml	10	12.5	15	20

Column doses are the beginner row's opening, standard, upper and ceiling figures from dose_protocols. Unit marks are arithmetic.

Supplies for one cycle

One on-cycle runs 12 weeks followed by 4 weeks off, from the engine catalog. Multiplied out at the standard dose and your mix, that is what the cycle costs in consumables.

Bacteriostatic water bottle size

Supplies for one on-cycle
Cycle length	12 weeks on, 4 weeks off
Administrations per week	7
Total administrations	84
Vials of 10 mg	3
Insulin syringes	84 (30-unit holds the draw)
Bacteriostatic water	6 ml, 1 bottle of 10 ml

Cycle length, loading phase and taper from PEPTIDE_CATALOG. Administrations per week derived from the frequency string on the dose row. Counts are arithmetic.

Save your reconstitution. Get the protocol it belongs in.

Free founding-member access while spots last. We'll send your reconstitution + a link to claim your slot.

About Sermorelin

Sermorelin is the first twenty-nine amino acids of growth hormone releasing hormone, the shortest fragment that retains the parent hormone's activity at its receptor. Structure-activity work through the 1980s and 1990s established that boundary, and human studies from the same period measured the growth hormone response to it by intravenous, subcutaneous and intranasal routes.

It has a regulatory history most of the catalog does not. Two products were approved in the United States: Geref for idiopathic growth hormone deficiency in children with growth failure, approved 26 September 1997, and a lower-strength presentation for evaluating the pituitary's capacity to secrete growth hormone, approved 28 December 1990. Approval of both was withdrawn effective 18 June 2009 after the holder discontinued them, and the FDA recorded that the withdrawal was not for reasons of safety or effectiveness. That distinction is the whole point of mentioning it.

The finding most often cited in an ageing context is a 1992 study in the Journal of Clinical Endocrinology and Metabolism reporting that twice-daily administration reversed the decline in growth hormone and IGF-1 seen in older men. Sermorelin is also named explicitly on the World Anti-Doping Agency prohibited list, in the growth hormone releasing factors class of section S2, prohibited at all times.

Administration and cycling

Administration and cycling reference
Route	subcutaneous
Timing	Bedtime
Catalog frequency	once daily
Cycle	12 weeks on, 4 weeks off
Taper before the off period	Not specified
Loading phase	None
Weight sensitive	No

Catalog note: Inject subcutaneously at bedtime. One of the oldest and most well-studied GH-releasing peptides.

Every row above is read from PEPTIDE_CATALOG, the engine catalog, and the note is quoted verbatim rather than paraphrased.

When this would not be recommended for you

A public page cannot know your health data, so it cannot tell you whether a compound is appropriate. What it can do is list the conditions the engine's contraindication matrix associates with this compound, and what the engine does about each. In a generated protocol these resolve automatically and the reason is shown alongside the exclusion.

Health conditions and the engine's action
Condition	Engine action	Reason
Cancer history	Caution	GH-releasing peptides may increase IGF-1, which is involved in cell growth. Requires oncological clearance before use with cancer history.
Diabetes type1	Caution	GH-releasing peptides may increase blood sugar via GH-induced insulin resistance. Requires close blood sugar monitoring with type 1 diabetes.
Heart condition	Caution	GH-releasing peptides may affect fluid balance and cardiac load. Requires cardiological clearance with heart disease.
Diabetes type2	Monitored	GH-releasing peptides may moderately affect blood sugar. Monitor fasting glucose and HbA1c with type 2 diabetes.
Thyroid	Monitored	GH-releasing peptides may affect thyroid function. Monitor TSH, free T3, and free T4 with thyroid disease.
Kidney	Dose reduced (75%)	Reduced kidney function may affect peptide clearance. Dose reduction recommended with kidney disease.

Conditions, severities and reasons read verbatim from CONTRAINDICATION_RULES, the engine's contraindication matrix. This is not the full set of things worth raising with a clinician; it is the set the engine acts on.

Questions

How many syringe units is a sermorelin dose?: It depends on your water volume, which sets the concentration. A microgram dose from a milligram vial lands at a small unit mark, so the water volume matters more here than for a milligram-dosed compound. Enter both in the calculator, or read the combination off the reconstitution chart below.
When should sermorelin be taken?: The engine catalog specifies bedtime, and the dose row's frequency string says the same. The administration section on this page carries the catalog note verbatim rather than paraphrasing it. Growth hormone release is pulsatile and largest overnight, which is the reason the timing is part of the protocol rather than a convenience.
What does the experience level input change?: It selects a different row in the engine dose table, changing the opening dose, standard dose, upper dose and ceiling. At the highest level the dose table also allows splitting the daily amount across more than one administration, which the frequency column shows verbatim.
Was sermorelin ever an approved medicine?: Yes, in the United States, and it is no longer. Two products were approved, one in 1990 for pituitary testing and one in 1997 for idiopathic growth hormone deficiency in children. Approval of both was withdrawn effective 18 June 2009 after the holder discontinued them, and the FDA determined the withdrawal was not for reasons of safety or effectiveness. A withdrawal for commercial reasons and a withdrawal for safety reasons are very different things, and only one of them happened here.
Does body weight change the sermorelin dose?: No. The engine catalog does not flag sermorelin weight sensitive and the dose calculator applies no generic weight scaling, so the tool leaves the target alone. Some peptides do carry a per-kilogram factor and the tool applies it for those.
Does sermorelin need cycling?: The engine catalog carries an on-period and an off-period for it, both shown on this page and used by the supplies plan.
Is sermorelin banned in drug-tested sport?: Yes. The World Anti-Doping Agency names sermorelin in the growth hormone releasing factors class of section S2, prohibited at all times, in and out of competition. The same class covers growth hormone releasing hormone analogues generally and growth hormone secretagogues. If you compete under anti-doping rules, check the current list directly.
When is sermorelin not appropriate?: The conditions table on this page lists every health condition the engine's contraindication matrix associates with this compound and its category, with the engine's own stated reason and whether it blocks, cautions, monitors or reduces the dose.
Where do the numbers on this page come from?: The dose table, the ceilings and the frequency come from the Klarovel engine's own dose table, the same rows the protocol generator doses from. Route, timing, cycling and weight sensitivity come from the engine catalog. Nothing on this page is a number someone typed into an article, which is the failure mode most dosing pages share.
Is this calculator free?: Yes. No account, no paywall, no usage limit. The protocol engine behind it is a separate product, but the calculator is open.
Does Klarovel sell this peptide?: No. Klarovel is the protocol layer: a questionnaire, a deterministic rules engine and a generated protocol. Any product is fulfilled by partner suppliers, not by Klarovel.
Is this medical advice?: No. It is arithmetic over published dose data, presented as a reference. It is not a prescription and not a recommendation to use any compound. Discuss peptide use with a qualified clinician.

Other peptide calculators

References

These papers cover sermorelin and the growth hormone releasing hormone fragment it is: the structure-activity work that defined the active sequence, human dose-response and pharmacokinetic studies by several routes, the paediatric growth trials, the study of twice-daily administration in older men, and reviews of its clinical use. They are not the source of the dose figures on this page.

The dose figures on this page are not sourced from these papers. They are read from the Klarovel engine's own dose table, which is cited inline wherever a number appears. These references cover mechanism, pharmacology and clinical context.

12 references, every identifier resolved against NCBI on 2026-08-03. Per peptide, a relevance-sorted esearch was run and every returned id was resolved through esummary. Any id esummary could not resolve was dropped, and any record carrying the 'Retracted Publication' pubtype was dropped. Titles, journals, years and first authors below are the values esummary returned, not authored text. One retracted record was dropped: PMID 37696839 (thymosin beta 4 query). Regenerated 2026-08-03 for cjc1295_no_dac, ipamorelin, pt141, retatrutide, aod9604 and sermorelin using the same esearch + esummary procedure; no record was added whose esummary payload lacked a title, journal or first author.

1.Prakash A et al. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999. PMID 18031173
2.Walker RF et al. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clin Interv Aging 2006. PMID 18046908 PMC2699646
3.Corpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1992. PMID 1379256
4.Vance ML et al. The effect of intravenous, subcutaneous, and intranasal GH-RH analog, [Nle27]GHRH(1-29)-NH2, on growth hormone secretion in normal men: dose-response relationships. Clin Pharmacol Ther 1986. PMID 3096623
5.Barron JL et al. Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men. Peptides 1985. PMID 2866496
6.Wilton P et al. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl 1993. PMID 8329825
7.Neyzi O et al. Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. Acta Paediatr Suppl 1993. PMID 8329826
8.Schwartz ID et al. Growth during and after a trial of growth hormone releasing hormone 1-29 in children with idiopathic short stature or growth hormone neurosecretory dysfunction. J Pediatr Endocrinol Metab 2000. PMID 10905389
9.Lance VA et al. Super-active analogs of growth hormone-releasing factor (1-29)-amide. Biochem Biophys Res Commun 1984. PMID 6231028
10.Cervini LA et al. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies. J Med Chem 1998. PMID 9513600
11.Khorram O et al. Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women. J Clin Endocrinol Metab 1997. PMID 9360512
12.Barabutis N et al. A glimpse at growth hormone-releasing hormone cosmos. Clin Exp Pharmacol Physiol 2020. PMID 32289177 PMC7426234

Beyond the arithmetic

Your health data, your protocol.

A calculator converts a dose into syringe units. The Klarovel engine decides the dose: it reads your health data, resolves contraindications, sets the envelope by experience level, removes incompatible pairs and builds the cycling and monitoring schedule. Blood work is optional and sharpens the result. It is never required.